文献速递肾小球疾病慢性肾脏病

Alport综合征中蛋白尿、eGFR下降与肾衰竭路径

Proteinuria, eGFR Decline, and the Pathway to Kidney Failure in Alport Syndrome.
PubMed 文献 · J Am Soc Nephrol · 2026-10-28

本文综述Alport综合征中蛋白尿与eGFR下降至肾衰竭的证据,聚焦足细胞功能障碍相关可部分逆转的蛋白尿和足细胞丢失/肾小球硬化相关难逆转的蛋白尿。基于活检的标志物提供疾病分期信息,但其与肾衰竭风险的定量关系尚不明确。Alport综合征终点框架应纳入基因型、性别、年龄、基线蛋白尿、基线eGFR、病程及非线性轨迹。

要点

  • 蛋白尿源于GBM通透性异常、足细胞足突融合、足细胞脱落和肾小球硬化。
  • eGFR下降是累积肾单位丢失和进展至肾衰竭的后期读数。
  • 活检标志物当前最强作用是靶点结合和通路修饰,与肾衰竭风险定量关系未明。

核心结论

  • Alport综合征临床试验终点选择需能报告疾病活动并预测有意义的临床获益,且试验规模和时长可行。

研究设计与样本

  • 本文为综述,检索范围未在摘要中报告。

主要发现

  • 蛋白尿从Alport综合征早期阶段出现,源于GBM通透性异常、足细胞足突融合、足细胞脱落和肾小球硬化。
  • eGFR下降是累积肾单位丢失和进展至肾衰竭的后期读数。
  • 蛋白尿中足细胞功能障碍伴足突融合可能部分可逆,而足细胞丢失和肾小球硬化相关蛋白尿较难逆转。
  • 蛋白尿组分的相对贡献可能随基因型、性别、年龄和病程变化。
  • 基于活检的标志物提供疾病通路上的分期信息,但与肾衰竭风险的定量关系尚不完全明确。

关键数值与推荐

  • 活检标志物包括胶原α3α4α5(IV)定位、GBM超微结构、足细胞足突宽度、肾小球硬化和肾小管间质纤维化。
  • Alport综合征终点框架应纳入基因型、性别、年龄、基线蛋白尿、基线eGFR、病程及蛋白尿和eGFR下降的预期非线性轨迹。

临床怎么用

  • 临床可依据蛋白尿和eGFR轨迹评估Alport综合征疾病活动与进展。
  • 活检标志物可用于评估靶点结合和通路修饰,但不宜单独用于定量预测肾衰竭风险。

局限性

  • 活检标志物变化与肾衰竭风险之间的定量关系尚不完全明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alport syndrome is a genetic disorder caused by pathogenic variants in COL4A3, COL4A4, or COL4A5, which encode the α3, α4, and α5 chains of type IV collagen. These chains form the collagen α3α4α5(IV) network required for basement membrane function in the kidney, inner ear, and eye. In the kidney, impaired production, assembly, or localization of the α3α4α5 network leads to abnormal glomerular basement membrane (GBM) composition, podocyte dysfunction, proteinuria, glomerulosclerosis, progressive loss of filtration capacity, and kidney failure. End point selection for clinical trials in Alport syndrome requires measures that report disease activity and predict meaningful clinical benefit in trials of feasible size and duration. Proteinuria arises from early stages of Alport pathogenesis: abnormal GBM permeability, podocyte foot-process effacement, podocyte detachment, and glomerulosclerosis. eGFR decline is a later readout of cumulative nephron loss and progression toward kidney failure. This review examines the evidence linking proteinuria and eGFR decline to kidney failure in Alport syndrome, focusing on two contributors to proteinuria: 1) podocyte dysfunction with foot-process effacement, which may be partially modifiable, and 2) proteinuria associated with podocyte loss and glomerulosclerosis, which is less likely to be reversible. The relative contribution of these components may vary with genotype, sex, age, and disease duration. Biopsy-based markers, such as collagen α3α4α5(IV) localization, GBM ultrastructure, podocyte foot-process width, glomerulosclerosis, and tubulointerstitial fibrosis, provide staging information along the disease pathway. The current role of these biopsy markers is strongest for target engagement and pathway modification, because quantitative relationships between changes in these markers and kidney failure risk remain incompletely defined. An end point framework for Alport syndrome should account for genotype, sex, age, baseline proteinuria, baseline eGFR, disease duration, and the expected nonlinear trajectories of proteinuria and eGFR decline.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Gale, Miner, Rheault, et al. Proteinuria, eGFR Decline, and the Pathway to Kidney Failure in Alport Syndrome. J Am Soc Nephrol. 2026. PMID: 42949772. doi:10.1681/ASN.0000001318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。